## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.4% below STRENGTH zone (3.0-6.0%); PEG 1.47 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($342.80)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Valley National Advisers Inc. Raises Stock Holdings in Stryker Corporation $SYK**
- Source: MarketBeat | 20251228T130540 | Bullish | Relevance: 100%
- Valley National Advisers Inc. significantly increased its stake in Stryker Corporation (NYSE:SYK) by 2,107.3% in the third quarter, bringing their total holdings to 5,717 shares valued at $2.11 million. This increase comes as Stryker reported strong Q3 earnings, beating analyst estimates, and raised its quarterly dividend. Despite notable insider selling, institutional investors collectively own 77.09% of the company's stock.

**2. NovaPoint Capital LLC Invests $1.06 Million in Stryker Corporation $SYK**
- Source: MarketBeat | 20251228T120455 | Somewhat-Bullish | Relevance: 100%
- NovaPoint Capital LLC has invested $1.06 million in Stryker Corporation (NYSE:SYK) by acquiring 2,857 shares. Other hedge funds have also increased their stakes, with institutional investors now owning 77.09% of the stock. Analysts currently rate Stryker as a "Moderate Buy" with a consensus price target of $431.84.

**3. How Investors May Respond To Stryker (SYK) Dividend Hike and Leadership Reshuffle**
- Source: Simply Wall Street | 20251225T062301 | Somewhat-Bullish | Relevance: 100%
- Stryker (SYK) recently increased its quarterly dividend by 4.8% to US$0.88 per share and announced leadership changes, including Spencer Stiles becoming President and COO. These moves reinforce the company's capital allocation priorities and investment appeal, particularly as it focuses on resolving supply chain issues and securing EU product approvals. Stryker's long-term forecast projects significant revenue and earnings growth by 2028, leading to a fair value estimate suggesting a 21% upside.

**4. Stryker Stock (SYK) After the Bell on Dec. 24, 2025: Latest News, Forecasts, and What to Watch Before the Next Market Open**
- Source: ts2.tech | 20251225T035429 | Somewhat-Bullish | Relevance: 100%
- Stryker Corporation (SYK) saw minimal movement on Christmas Eve, closing at $354.74 and trading slightly lower in thin after-hours volume, reflective of a holiday-shortened trading day rather than a fundamental change. Analysts maintain a "Hold" rating, but see potential upside, with the stock positioned well above its 52-week low. Investors are focusing on the upcoming dividend payment and a leadership transition in January, while comparing Stryker's diversified medical technology model against pure-play robotics companies.

**5. Intuitive Surgical vs. Stryker: Which MedTech Stock Has More Upside?**
- Source: The Globe and Mail | 20251224T130836 | Somewhat-Bullish | Relevance: 100%
- This article compares Intuitive Surgical (ISRG) and Stryker (SYK), two major MedTech companies, evaluating their upside potential based on growth leverage, revenue visibility, and strategic positioning. While Stryker offers diversification and stability, Intuitive Surgical, with its concentrated robotics exposure and higher margins, is suggested to have greater upside potential. However, ISRG carries higher valuation sensitivity and competition risks compared to SYK's steadier, but perhaps less explosive, growth profile.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Citizens | $440 | $0 | 0% |
| 2025-12-18 | Truist Securiti | $392 | $400 | -2% |
| 2025-12-11 | Citigroup | $420 | $455 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Citizens | up | Market Outperform |
| 2025-12-18 | Truist Securiti | main | Hold |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.76M) |
| Sells | 7 ($21.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Heavy insider selling: $21M sold (7 transactions in 90 days).
2. Long-term trend broken: trading 5.5% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 23.7x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Analyst sentiment negative (2 target cuts vs 0 raises). Insider selling cluster ($21.1M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $135.5B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 23.7 |
| Current P/E | 26.1 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.4% to -1.4% (-1.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.4pp (needs >3.0% for momentum thesis). Below SMA200 (0.94x), long-term trend not supportive. RSI neutral at 43. OFD pattern: -SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.42% (CS: 36) | Neutral |
| RSI_14 | 43.0 | Neutral |
| MACD Histogram | 0.23 | Bullish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 0.973x | Below |
| vs SMA200 | 0.945x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $354.28
- **Stop Loss:** $342.80 (3.2% risk)
- **Target:** $365.76 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 114
- **Position Value:** $40,387.92
- **Portfolio %:** 40.39%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*